World

Eli Lilly’s Weight-Loss Pill Foundayo Approved in the UK

Eli Lilly's Foundayo pill receives approval in the UK, marking significant competition with Novo Nordisk's Wegovy.

11 August 2026Tagblick Newsdesk

AI-generatedWritten by an AI system, editorially responsible — how we work

Archive photo: Eli Lilly’s Weight-Loss Pill Foundayo Approved in the UK — Archive photoPhoto: pasa47 · Flickr · BY

Eli Lilly's weight-loss pill, Foundayo, has been granted approval in the United Kingdom, marking it as the second GLP-1 oral medication to receive such clearance in the country. This follows the approval of Novo Nordisk's Wegovy pill, intensifying the competition between the two pharmaceutical companies.

The win for Eli Lilly is part of a broader strategy to extend its weight-loss medication offerings globally, following previous successes in the U.S. market. This development allows Eli Lilly to enter the UK market, expanding the reach of its weight-loss solutions.

This item was written by an AI system on the basis of the headlines and short teasers of the independently operating newsrooms named below. We disclose this under Art. 50(4), second subparagraph, of Regulation (EU) 2024/1689 (AI Act). Before publication we check origin and verifiability — anything that appears in only one place is not published — as well as language, substance and legally sensitive content. No separate substantive review of each individual item by a natural person takes place; we therefore do not rely on the exemption in Art. 50(4), second subparagraph, of the AI Act. Editorial responsibility for this publication rests with the person named in the imprint (§ 18 Abs. 2 MStV). Please report errors to [email protected] — we will correct or remove the item. Full reports are available from the sources listed.